17th Annual Pacific Northwest Prostate Cancer Conference
Registration is based on location
Fee: $35 (Includes lunch, conference materials and parking.)
This is a multi-site conference with locations at OHSU (Portland, OR), UW (Seattle, WA) and UBC (Vancouver, BC).
Saturday, September 23, 2017
At the premier prostate cancer conference in the Northwest for patients and their families, the OHSU Knight Cancer Institute, in conjunction with the University of Washington School of Medicine and the University of British Columbia Cancer Agency Research Centre bring together the foremost experts on prostate cancer to present and discuss the latest findings regarding prostate cancer treatment, prevention, survivorship and scientific progress.
The conference will provide a state-of-the-art update on prevention and early detection of prostate cancer, treatment of localized prostate cancer, medical management of advanced prostate cancer, and current status of knowledge about the role of nutrition in prostate cancer. Highlights of recent scientific progress and a survey of current clinical trials likely to change the standard of care in the coming years will be prominently featured.
In addition, attendees will learn about coping with the diagnosis of prostate cancer. Sexuality in prostate cancer survivors will also be addressed.
The program includes ample opportunities for audience participation.
Who should attend?
- Patients with prostate cancer
- Men at risk for prostate cancer
- Families and loved ones
- Advocates for progress against prostate cancer
- Anyone with an interest in prostate cancer
Recordings of 2016 conference
Recordings of 2016 conferenceSession 1 (8:30 - 10 a.m.)
Topics: All you need to know about robotic prostatectomy by Larry Goldenberg, M.D.
What's new in radiation therapy to treat localized disease? by Jennifer Goulart, M.D.
What to do for PSA recurrence after surgery or radiation therapy by Julie N. Graff, M.D.
Do genes make a difference? by Intan Schrader, M.D.
Session 2 (10:10 - 12:10 p.m.)
Topics: Question & Answer period (before break sessions)
A primer on genomics of prostate cancer by Alex Wyatt, M.D.
Current Management of Castration-resistant Prostate Cancer by Tomasz M. Beer, M.D.
New Treatments on the Horizon by Kim Chi, M.D.
Question & Answer period (after break sessions)
Session 3 (1 - 3:10 p.m.)
Topics: Hormone therapy and cardiovascular risk: what do we know by Celestia S. Higano, M.D., F.A.C.P.
Exercise and prostate cancer by Sarah Weller, B.C.A.K., C.S.E.P.
If I had known... by David Kuhl, M.D.
Question & Answer period (afternoon sessions)
2016 Conference Agenda
Past printed materials are available for $10.00.For more information call 503-494-1091 or email email@example.com.
- Session 1: Robotic Prostatectomy (Ellis, UW); Radiation Therapy (Hung, OHSU); PSA Recurrence (Graff, OHSU); High Risk Prostate Cancer (Goldenberg, UBC)
- Session 2: Q&A panel (session 1 speakers); Translational Research (Alumkal, OHSU); Castration-resistant Pca (Beer, OHSU); New Treatments (Higano, UW); Q&A panel (session 2 speakers)
- Session 3: Exercise (Winters-Stone, OHSU); Sexuality/Intimacy (Zarowski, UBC); Survivorship (Lutz, UBC)
*Note: The recording for Dr. Mark Moyad's presentation is unavailable.